
What are the challenges of predicting durable CR in HR-MDS?
Julie Braish, MD, a fellow at Moffitt Cancer Center, discusses a retrospective study to determine if durable complete remission, defined as lasting at least six months, could be predicted using baseline clinical and molecular characteristics in patients with higher-risk myelodysplastic syndromes.





